Amgen’s Phase III GAUSS-2 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-2) trial of evolocumab in patients with high cholesterol who can’t tolerate statins, met its co-primary endpoints: the percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C), and the mean percent reduction from baseline in LDL-C.   Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9...